Cargando…
Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models
Recent advances in cancer treatment with checkpoint blockade of receptors such as CTLA-4 and PD-1 have demonstrated that combinations of agents with complementary immunomodulatory effects have the potential to enhance antitumor activity as compared to single agents. We investigated the efficacy of i...
Autores principales: | Lewis, Katherine E., Selby, Mark J., Masters, Gregg, Valle, Jose, Dito, Gennaro, Curtis, Wendy R., Garcia, Richard, Mink, Kathy A., Waggie, Kimberly S., Holdren, Matthew S., Grosso, Joseph F., Korman, Alan J., Jure-Kunkel, Maria, Dillon, Stacey R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739581/ https://www.ncbi.nlm.nih.gov/pubmed/29296539 http://dx.doi.org/10.1080/2162402X.2017.1377873 |
Ejemplares similares
-
Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models
por: Jure-Kunkel, Maria, et al.
Publicado: (2013) -
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
por: Peggs, Karl S., et al.
Publicado: (2009) -
Activated CTLA‐4‐independent immunosuppression of Treg cells disturbs CTLA‐4 blockade‐mediated antitumor immunity
por: Watanabe, Tomofumi, et al.
Publicado: (2023) -
Protective Immunity to Nematode Infection Is Induced by CTLA-4 Blockade
por: McCoy, Kathy, et al.
Publicado: (1997) -
Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer
por: Coutzac, Clélia, et al.
Publicado: (2020)